http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2011203202-B2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_059babf90e455b4228aeb41f2eed9887
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
filingDate 2011-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2014-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afa0eb06c7c06b2795dea5fcaa75575a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90e53ec0cb9a184945fcaf99b47212f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f113398d976833dc3c1ae71430ca73a4
publicationDate 2014-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AU-2011203202-B2
titleOfInvention Methods of using sustained release aminopyridine compositions
abstract A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition. WO 20051099701 PCT/US2005/012427 35 Treatment means over time ** e 25 ------ CD O --- Racebo (N=47) 0 + Farrpridine Responders (N=58) Fi.1 titration 1 st stable 2nd stable 3rd stable *:Significantly better than placebo and fampridine non-responders &P < 0.001 for each). 5Significantly better than farnpridine non-responders Fig. 10
priorityDate 2004-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412088289
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483979
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419516398
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419529444
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID152774259
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7314
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407174045
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415224349
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419552760
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5918
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9956
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID423390420
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3383616
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1727
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6781
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID447638
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54680660
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419524143
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5391
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6380
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10439
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419513769
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6506
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410768459
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID114781
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419530952
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419584599
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468172510

Total number of triples: 41.